Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2025-03-14 00:00:00 ET · period of report 2025-03-12 · accession 0001415889-25-008115 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-14 | 2025-03-12 | KNSA | Ragosa Mark | CFO | S - Sale+OE | $22.25 | -36.4K | 23.0K | -61% | -$809.3K |
| D | 2025-03-14 | 2025-03-12 | KNSA | Ragosa Mark | CFO | M - OptEx | $11.97 | +36.4K | 59.3K | +158% | +$435.4K |
| D | 2025-03-14 | 2025-03-12 | KNSA | Ragosa Mark | CFO | M - OptEx | $0.00 | -36.4K | 28.3K | -56% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2025-03-12 | S | D | 36,372 | $22.25 | 22,958 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $22.25 and $22.27. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 2 | Common | Class A Ordinary Share | 2025-03-12 | M | A | 36,372 | $11.97 | 59,330 | D | — | — | |
| 3 | Derivative | Share Option | 2025-03-12 | M | D | 36,372 | $0.00 | 28,288 | D | $11.97 · — to 2032-08-31 | 36,372 Class A Ordinary Share | (F3) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. |